
Aurobindo Pharma's subsidiary, APL Healthcare, has received final approval from the US health regulator, the USFDA, for generic Sevelamer hydrochloride tablets. The approval allows Aurobindo Pharma to manufacture and market Sevelamer hydrochloride tablets in strengths of 400 mg and 800 mg. The company stated that these generic tablets are bioequivalent and therapeutically equivalent to the reference listed drug, Renagel tablets, manufactured by Genzyme Corporation.
Like
Save
Share